Growth finance vs the traditional approach: what actually beats what for healthcare and life sciences in the Benelux region

This edition of the Growth Broker playbook is written for commercial leaders at healthtech, medtech, and life-sciences companies operating in the Benelux region. In this market, Benelux buyers reward multilingual specificity and a pitch that respects local nuance, so the way you install growth finance has to be shaped to that reality from day one.

The debate about growth finance is often framed as replacement — new model wipes out old. That framing is wrong. The right question is where each approach wins.

Growth finance wins on speed of learning, targeting precision, and cost per outcome. It is running growth as a portfolio with a return-on-invested-capital lens, and it compounds in ways the traditional approach cannot match.

The traditional approach wins on relationship depth, brand consistency, and situations where the buyer has already self-identified. Ignoring that is why some teams' first growth finance attempt underperforms — they replace the wrong parts.

Inside healthcare and life sciences, the binding constraint is almost always regulated-sale cycle length, not intent, and in the Benelux region it is compounded by the fact that local nuance and language fit, not scale is what actually gates growth. Growth finance is only useful here when it is pointed at both constraints at once.

Combine them deliberately. Use growth finance to find and qualify; use the traditional approach to close and expand. The seam between them is where most pipeline is lost or won.

Metric to watch when running both: CAC payback and gross margin, plus source attribution. The two approaches should not cannibalise each other; if they do, your handoff is broken.

The failure mode of running both is optimising for growth rate at any cost — usually because the traditional team feels threatened and the new model is starved of context.

Companies that get this right end up with a hybrid engine that outperforms either pure model. Companies that pick one and evangelise it lose to the ones that combine.

Concretely for healthcare and life sciences in the Benelux region: the healthcare teams that install this get past procurement instead of dying in it, and one anchored Benelux customer becomes the reference the rest of the region asks for. That is the reason it is worth installing growth finance deliberately for this market rather than importing a playbook designed for somewhere else.